Sovereign AI Backs UK Startup Potential Sciences in Eight-Figure Funding Round
Government venture fund invests in AI chemistry startup aiming to accelerate drug discovery and reindustrialise Britain.
By The SME Chronicle Newsroom
••4 min read
AI
Generic image of advanced computer hardware and circuitry.
Potential Sciences, a British startup focused on using artificial intelligence to redefine chemistry and accelerate drug discovery, has secured significant backing from the UK Government’s Sovereign AI venture fund.
The company announced an eight-figure funding round today, which includes not only investment but also crucial access to compute power – the processing capability essential for training advanced AI models. This support underscores the UK's commitment to fostering homegrown companies at the forefront of critical technologies, driving the nation's reindustrialisation and the next wave of AI innovation.
Potential Sciences is developing a novel approach to AI in chemistry, focusing on the fundamental laws of physics rather than relying solely on existing experimental data. This method has the potential to dramatically reduce the cost of AI calculations for chemical design, making it up to 100 times cheaper and potentially unlocking new avenues for discovering treatments for diseases such as cancer and Parkinson’s.
Sovereign AI, described as the government’s significant investment in promising early-stage AI companies, aims to help these businesses grow and succeed from the UK. It combines the agility of venture capital with state backing to support British AI innovators.
“
"Potential Sciences is a startup that’s grasping an opportunity Britain is uniquely well-placed to capitalise on: using our deep expertise in data, fundamental science and computing to potentially unleash the next great wave of medical discovery."
“
"As a former chemical engineer, I know firsthand how the field can make a real difference; whether that’s discovering new medicines to treat and beat disease, or finding cheaper and more efficient ways to bring innovations to life."
“
"AI for drug discovery has learned almost everything the existing experimental record can teach it. The next leap needs new data, and the laws of physics can supply it, as long as your software can use modern hardware."
In addition to Sovereign AI, other investors in the round include Twin Path Ventures, Odyssey, Portfolio Ventures, Blue Wire Capital, rule30, Nauta Capital, and Lightfield Equity. Angel investment also came from notable figures such as Patrick Collison (co-founder of Stripe) and Chris Gibson (co-founder and former CEO of Recursion). The company will also receive advisory support from AI engineer Andrew Fitzgibbon and entrepreneur James Hawkins.
Sovereign AI is also providing access to advanced computing resources through the AI Research Resource, the UK’s national supercomputing network, including the Isambard-AI supercomputer located in Bristol.
“
"Drug discovery is an expensive and uncertain business and we still don’t have effective treatments and cures for many diseases. Potential Sciences has proposed an elegant solution: turning to the fundamentals of quantum science and AI. That could be a gamechanger and speaks to the ingenuity and inspiration that Sovereign AI seeks to foster into new businesses and products."
“
"I first met Hatem in Cambridge, and he immediately struck me as a formidable founder. He combines technical excellence with low ego and unapologetic ambition. He knows the science in extraordinary detail, but he’s also deliberate about bringing in people who are exceptional in areas different from his own."
This announcement follows the recent Budget, where the Chancellor confirmed an additional £140 million for Sovereign AI, including £60 million for fund investments and £80 million for its R&D Procurement Scheme. Sovereign AI will also expand its focus to Physical and Industrial AI, leveraging the UK's research strengths in areas like robotics and advanced manufacturing.
Startups supported by Sovereign AI are required to have a significant UK presence, creating well-paid jobs across the country and anchoring their operations, leadership, or talent base in Britain.
Based on information from the official source: Cabinet Office (05/11/2026)
